{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:45:39Z","timestamp":1759333539252},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.cll.2013.08.008","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T02:18:41Z","timestamp":1381889921000},"page":"881-890","source":"Crossref","is-referenced-by-count":1,"title":["Current Applications of Molecular Genetic Technologies to the Diagnosis and Treatment of Cutaneous Melanocytic Neoplasms"],"prefix":"10.1016","volume":"33","author":[{"given":"Muhammad","family":"Zulfiqar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew David","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2013.08.008_bib1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.5858\/2011-0048-RAIR.1","article-title":"Update on fluorescence in situ hybridization in melanoma","volume":"135","author":"Gerami","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cll.2013.08.008_bib2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5858\/2010-0682-ED.1","article-title":"Melanocytic lesions: current state of knowledge\u2014part II","volume":"135","author":"Zembowicz","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cll.2013.08.008_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5858\/2010-0146-RA.1","article-title":"Nevus\/melanocytoma\/melanoma","volume":"135","author":"Zembowicz","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cll.2013.08.008_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cll.2011.03.008","article-title":"Spitz nevi, atypical Spitzoid neoplasms, and Spitzoid melanoma","volume":"31","author":"Zedek","year":"2011","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.cll.2013.08.008_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5858\/2009-0503-RA.1","article-title":"Melanoma in children","volume":"135","author":"Paradela","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cll.2013.08.008_bib6","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1468-3083.2012.04686.x","article-title":"Spitzoid and non-Spitzoid melanoma in children, a prognostic comparative study","volume":"27","author":"Paradela","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cll.2013.08.008_bib7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24047","article-title":"The atypical Spitz tumor of uncertain biologic potential","volume":"115","author":"Ludgate","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archdermatol.2011.170","article-title":"Long-term outcome of Spitz-type melanocytic tumors","volume":"147","author":"Sepehr","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.cll.2013.08.008_bib9","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2013.08.008_bib10","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":"Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PAS.0b013e31820393ee","article-title":"Copy number variations and clinical outcome in atypical Spitz tumors","volume":"35","author":"Raskin","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/PAS.0b013e3181f0a749","article-title":"HRAS-mutated Spitz tumors, a subtype of Spitz tumors with distinct features","volume":"34","author":"van Engen-van Grunsven","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAS.0b013e318263648c","article-title":"Combined BRAFV600E-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes","volume":"37","author":"Busam","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/DAD.0b013e31828671bf","article-title":"Atypical Spitz tumors with 6q23 deletions: a clinical, histological, and molecular study","author":"Shen","year":"2013","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.cll.2013.08.008_bib15","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1097\/PAS.0b013e3181a1ef36","article-title":"Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma","volume":"33","author":"Gerami","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1600-0560.2011.01675.x","article-title":"Fillet of FISH","volume":"38","author":"McCalmont","year":"2011","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31822d5ff8","article-title":"Enhanced detection of Spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe","volume":"36","author":"Gammon","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib18","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/PAS.0b013e31824b1efd","article-title":"A\u00a0highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms","volume":"36","author":"Gerami","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib19","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/PAS.0b013e3181a92cbc","article-title":"Distinguishing epithelioid blue nevus from blue nevus-like melanoma using fluorescence in situ hybridization","volume":"33","author":"Pouryazdanparast","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jmoldx.2011.01.011","article-title":"Copy number gains in 11q13 and 8q34 are highly linked to prognosis in cutaneous malignant melanoma","volume":"13","author":"Gerami","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.cll.2013.08.008_bib21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/PAS.0b013e3182753de6","article-title":"Risk assessment for atypical Spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations","volume":"37","author":"Gerami","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0625.2008.00805.x","article-title":"Molecular diagnosis in dermatopathology: what makes sense, and what doesn't","volume":"18","author":"Braun-Falco","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.cll.2013.08.008_bib23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/cup.12021","article-title":"Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome","volume":"39","author":"Held","year":"2012","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.cll.2013.08.008_bib24","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1200\/JCO.2007.12.0253","article-title":"Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients","volume":"253","author":"Ives","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2013.08.008_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1529-8019.2012.01487.x","article-title":"New therapeutical strategies in the treatment of metastatic disease","volume":"25","author":"Julia","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.cll.2013.08.008_bib26","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib27","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment","volume":"26","author":"Fong","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2013.08.008_bib28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2009-0028","article-title":"What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?","volume":"14","author":"Robert","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.cll.2013.08.008_bib29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2013.08.008_bib30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.cll.2013.08.008_bib31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2013.08.008_bib32","unstructured":"Available at: http:\/\/www.zelboraf.com. Accessed September 7, 2013."},{"key":"10.1016\/j.cll.2013.08.008_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"BRIM-2: an open label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2013.08.008_bib34","unstructured":"A study of RO5185426 in comparison with dacarbazine in previously untreated patients with metastatic melanoma (BRIM 3). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01006980. Accessed September 7, 2013."},{"key":"10.1016\/j.cll.2013.08.008_bib35","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2013.08.008_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.cll.2013.08.008_bib37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cll.2013.08.008_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cll.2013.08.008_bib39","unstructured":"Investigational drug, GSK2118436 (dabrafenib), reported to demonstrate clinical activity in BRAF-mutant patients with brain metastases (BREAK-MB trial). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01266967. Accessed September 7, 2013."},{"key":"10.1016\/j.cll.2013.08.008_bib40","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2007.14.0707","article-title":"Major response to imatinib mesylate in KIT-mutated melanoma","volume":"26","author":"Hodi","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cll.2013.08.008_bib41","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib42","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6602529","article-title":"Lack of clinical efficacy of imatinib in metastatic melanoma","volume":"92","author":"Ugurel","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cll.2013.08.008_bib44","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cll.2013.08.008_bib45","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271213000711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271213000711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T18:19:21Z","timestamp":1716056361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271213000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0272271213000711"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2013.08.008","relation":{},"ISSN":["0272-2712"],"issn-type":[{"type":"print","value":"0272-2712"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}